Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189875 · ClinicalTrials.gov registry record
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)
A clinical trial, sponsored by AstraZeneca.
- Completed
- Registry status
- 830
- Enrollment target
NCT03189875: Completed study, sponsored by AstraZeneca.
NCT03189875 is a clinical trial that has completed, run by AstraZeneca. The registered enrollment target is 830 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03189875 has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 830 participants
- Enrollment target
Study Summary
SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health status assessments (PROs), and health care resource utilization (HCRU) in a general population of moderate-to-severe SLE patients.
Primary Outcome
Total Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score and score change from Baseline in patients with high and/or low status interferon 1 gene signature at Baseline after 6, 12, 18, 24, 30 and 36 months of follow-up.
Interventions
- OTHER Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 830 participants |
| Start Date | 2017-06-28 |
| Est. Completion | 2022-11-18 |
What the finished NCT03189875 record still lists
NCT03189875 is an observational study that tracks outcomes without assigning an intervention. The registered 830 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care is the first listed.
NCT03189875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03189875 about?
NCT03189875 is a clinical study titled "Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)". SPOCS is an international, multicenter, prospective observational cohort study with bi-annual study visits over a 3-year follow-up designed to systematically describe the comprehensive SLE patient-journey regarding clinical features, disease progression and treatment patterns, SLE outcomes, health s...
What is the current status of trial NCT03189875?
This trial is currently completed. The enrollment target is 830 participants. The study started on 2017-06-28. Estimated completion is 2022-11-18.
What interventions are being tested in trial NCT03189875?
The interventions under investigation include: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT03189875?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05067283 · 830 participants · Phase 1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- NCT06592924 · 830 participants · Phase 3
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
- NCT06868277 · 830 participants · Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- NCT06910553 · 832 participants
IBD Pregnancy Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI